Drug Profile
RG 7713
Alternative Names: RG7713Latest Information Update: 28 Dec 2018
Price :
$50
*
At a glance
- Originator Roche
- Class Antipsychotics
- Mechanism of Action Vasopressin 1a receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pervasive child development disorders
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for phase-I development in Pervasive-child-development-disorders in USA (IV)
- 03 Nov 2015 Efficacy data from a phase I trial in Pervasive child development disorders released by Roche
- 02 Nov 2015 Roche completes a phase I trial for Pervasive child development disorders in USA